Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Vallböhmer, D; Drebber, U; Schneider, P M; Baldus, S; Bollschweiler, E; Brabender, J; Warnecke-Eberz, U; Mönig, S; Hölscher, A H; Metzger, R (2009). Surviving expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis. Journal of Surgical Oncology, 99(7):409-413.

Full text not available from this repository.

Abstract

BACKGROUND AND OBJECTIVES: Neoadjuvant therapy is applied to improve the prognosis associated with advanced gastric cancer. Only patients with a major response seem to have a survival benefit. Predictive markers to allow individualisation of treatment could be helpful. We examined the association of survivin protein expression with histopathologic response to neoadjuvant chemotherapy and prognosis in patients with gastric cancer. METHODS: Forty patients with gastric cancer received neoadjuvant chemotherapy. Afterwards, 38 patients underwent total gastrectomy, while 2 patients received definitive chemotherapy because of tumour progression. Histomorphologic regression was defined as major response when resected specimens contained <10% tumour cells. Intratumoural survivin expression was determined by immunohistochemistry in pre- and post-therapeutic specimens and correlated with clinicopathologic parameters. RESULTS: The pre- and post-therapeutic intratumoural survivin protein expression was not associated with histomorphologic regression. Post-therapeutic survivin expression did not have prognostic impact. A significant association was detected between pre-therapeutic survivin levels and prognosis: patients with a higher survivin protein expression showed a significant survival benefit. In multivariate analysis pre-therapeutic survivin expression was characterised as an independent prognostic marker, besides pN-status and histopathologic regression. CONCLUSIONS: The pre-therapeutic survivin protein expression seems to be an independent prognostic marker in the multimodality treatment of advanced gastric cancer.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Visceral and Transplantation Surgery
04 Faculty of Medicine > University Hospital Zurich > Division of Surgical Research
DDC:610 Medicine & health
Language:English
Date:2009
Deposited On:28 Jan 2010 12:15
Last Modified:27 Nov 2013 18:09
Publisher:Wiley-Blackwell
ISSN:0022-4790
Publisher DOI:10.1002/jso.21271
PubMed ID:19347901
Citations:Web of Science®. Times Cited: 10
Google Scholar™
Scopus®. Citation Count: 13

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page